Europe Bioresorbable Vascular Scaffold Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Bioresorbable vascular scaffolds represent a transformative category of temporary implantable devices used primarily in percutaneous coronary and peripheral interventions, designed to provide short-term vessel support before naturally degrading. The European market for these scaffolds is estimated at approximately $0.2 billion in 2025, reflecting a relatively early-stage but rapidly advancing therapeutic segment within the broader cardiovascular device landscape. The market stands to benefit from the wider European polymeric biomaterials sector, which exceeded $15.5 billion in 2023, underscoring the strong industrial and clinical infrastructure supporting advanced medical device development across the EU.

• •Market valued at ~$0.2 billion in Europe in 2025 with a 15.1% CAGR
• •Bioresorbable scaffolds dissolve after vessel healing, avoiding permanent implant complications
• •European polymeric biomaterials market exceeded $15.5 billion in 2023, providing strong industry foundation

The primary catalyst for market expansion is the escalating burden of cardiovascular disease across an aging European demographic, combined with a clinical preference for devices that restore natural vessel function without leaving behind permanent metallic hardware. Advances in next-generation bioresorbable materials, including enhanced PLLA-based polymers and magnesium alloys with improved mechanical properties, have reinvigorated confidence following earlier platform setbacks. Additional momentum stems from the integration of additive manufacturing and 3D-printing technologies enabling patient-specific scaffold geometries, as well as the broader trend toward minimally invasive interventional procedures across European healthcare systems.

• •Aging European population and rising cardiovascular disease prevalence driving clinical demand
• •Advances in bioresorbable polymers and magnesium alloys with improved mechanical performance
• •Additive manufacturing and 3D-printing enabling patient-specific custom scaffold solutions

The European BVS market is segmented by material type into polymer-based scaffolds (predominantly PLLA and PCL), magnesium-alloy platforms, and emerging bioresorbable composites incorporating electrospun and shape-memory polymer technologies. By clinical application, coronary artery disease represents the largest segment, while peripheral arterial disease, particularly lower limb interventions, is emerging as a high-growth frontier for bioresorbable scaffold deployment. Geographically, Western Europe, led by Germany, France, and the UK, dominates adoption due to advanced healthcare infrastructure, higher procedural volumes, and established reimbursement frameworks, while Eastern European markets are gradually expanding access as healthcare investments grow.

• •Materials include PLLA/PCL polymers, magnesium alloys, and emerging bioresorbable composites
• •Coronary applications lead in volume, with peripheral arterial disease (lower limb) as a fast-growing segment
• •Western Europe (Germany, France, UK) leads adoption; Eastern Europe emerging with rising healthcare investment

What are the recent trends and outlook?

The market is moving toward next-generation bioresorbable scaffolds incorporating bioresorbable drug-eluting coatings, thinner strut profiles, and more predictable resorption kinetics to address earlier-generation limitations. Emerging manufacturing paradigms, including fused deposition modeling and selective laser sintering for patient-specific scaffolds, along with shape-memory polymers for minimally invasive delivery, are expected to redefine product differentiation through 2029. The broader hydrogel and electrospun scaffold sector, growing at over 10% annually, further supports ecosystem expansion. Over the forecast horizon through 2029, the European BVS market is well-positioned for sustained 15%-plus annual growth, driven by aging demographics, rising cardiovascular disease prevalence, and the compelling clinical value proposition of bioresorbable platforms that restore natural vessel physiology.

• •Next-generation scaffolds incorporate drug-eluting coatings and thinner strut profiles for improved safety profiles
• •Shape-memory polymers and electrospun fabrication methods are projected to grow rapidly through 2032
• •Long-term outlook through 2029 remains strongly positive, supported by aging demographics and clinical preference for bioresorbable solutions